Skip to main content
. 2018 Jan 23;11:1756285617753365. doi: 10.1177/1756285617753365

Figure 1.

Figure 1.

CLARITY and CLARITY Extension study plan.

Assessments of MRI activity were carried out when patients entered CLARITY Extension and after Weeks 24, 48, 72 and 96 of double-blind treatment, and at the start and end of a 6-month supplemental follow-up period (unless the final double-blind period assessment was within 4 weeks of the start of the supplemental follow up).

†patients who received placebo in CLARITY were assigned to treatment with cladribine 3.5 mg/kg in CLARITY Extension.

‡patients who received cladribine 3.5 mg/kg or 5.25 mg/kg in CLARITY were rerandomized to receive placebo or cladribine 3.5 mg/kg in CLARITY Extension.

PC 3.5 mg/kg, placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CP 3.5 mg/kg, cladribine 3.5 mg/kg in CLARITY/placebo in CLARITY Extension; CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg, cladribine 5.25 mg/kg in CLARITY/cladribine 3.5 mg/kg CLARITY Extension; CP 5.25 mg/kg, cladribine 5.25 mg/kg in CLARITY/placebo in CLARITY Extension; SUPF, supplemental follow up; MRI, magnetic resonance imaging; RRMS, relapsing–remitting multiple sclerosis.